132 related articles for article (PubMed ID: 3042913)
1. A combined regimen of subcutaneous lisuride and oral Madopar HBS in Parkinson's disease.
Chouza C; Caamaño JL; de Medina O; Aljanati R; Scaramelli A; Romero S
J Neural Transm Suppl; 1988; 27():61-70. PubMed ID: 3042913
[TBL] [Abstract][Full Text] [Related]
2. Single-dose studies of a slow-release preparation of levodopa and benserazide (Madopar HBS) in Parkinson's disease.
Marion MH; Stocchi F; Malcolm SL; Quinn NP; Jenner P; Marsden CD
Eur Neurol; 1987; 27 Suppl 1():54-8. PubMed ID: 3322837
[TBL] [Abstract][Full Text] [Related]
3. Substitution of standard Madopar by Madopar HBS in parkinsonians with fluctuations.
Chouza C; Romero S; de Medina O; Aljanati R; Scarmelli A; Caamano JL; Gonzales Panizza V
Eur Neurol; 1987; 27 Suppl 1():59-67. PubMed ID: 3428309
[TBL] [Abstract][Full Text] [Related]
4. Open multicenter trial with Madopar HBS in parkinsonian patients. Preliminary assessment after short-term treatment.
Jansen EN; Meerwaldt JD; Heersema T; van Manen J; Speelman JD
Eur Neurol; 1987; 27 Suppl 1():88-92. PubMed ID: 3322841
[TBL] [Abstract][Full Text] [Related]
5. A controlled release form of madopar in parkinsonian patients with advanced disease and marked fluctuations in motor performance.
Jensen NO; Dupont E; Hansen E; Mikkelsen B; Mikkelsen BO
Acta Neurol Scand; 1988 May; 77(5):422-5. PubMed ID: 3046226
[TBL] [Abstract][Full Text] [Related]
6. Subcutaneous lisuride infusion in Parkinson's disease: clinical results using different modes of administration.
Stocchi F; Ruggieri S; Antonini A; Baronti F; Brughitta G; Bellantuono P; Bravi D; Agnoli A
J Neural Transm Suppl; 1988; 27():27-33. PubMed ID: 3165437
[TBL] [Abstract][Full Text] [Related]
7. Open clinical study of Madopar HBS.
Ludin HP
Eur Neurol; 1987; 27 Suppl 1():73-5. PubMed ID: 3322838
[TBL] [Abstract][Full Text] [Related]
8. Madopar HBS in Parkinson patients with nocturnal akinesia.
Jansen EN; Meerwaldt JD
Clin Neurol Neurosurg; 1988; 90(1):35-9. PubMed ID: 3359732
[TBL] [Abstract][Full Text] [Related]
9. Clinical and pharmacokinetic observations with Madopar HBS in hospitalized patients with Parkinson's disease and motor fluctuations.
Poewe WH; Lees AJ; Stern GM
Eur Neurol; 1987; 27 Suppl 1():93-7. PubMed ID: 3322842
[TBL] [Abstract][Full Text] [Related]
10. Madopar HBS in the long-term treatment of parkinsonian patients with fluctuations in disability.
Rinne UK
Eur Neurol; 1987; 27 Suppl 1():120-5. PubMed ID: 3428305
[TBL] [Abstract][Full Text] [Related]
11. Madopar HBS in fluctuating parkinsonian patients: two-year treatment.
Pezzoli G; Tesei S; Ferrante C; Cossutta E; Zecchinelli A; Scarlato G
Mov Disord; 1988; 3(1):37-45. PubMed ID: 3050471
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness of Madopar HBS plus Madopar standard in patients with fluctuating Parkinson's disease: two years of follow-up.
Pacchetti C; Martignoni E; Sibilla L; Bruggi P; Turla M; Nappi G
Eur Neurol; 1990; 30(6):319-23. PubMed ID: 2289507
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of decarboxylase and levels of dopa and 3-O-methyldopa: a comparative study of benserazide versus carbidopa in rodents and of Madopar standard versus Madopar HBS in volunteers.
Da Prada M; Kettler R; Zürcher G; Schaffner R; Haefely WE
Eur Neurol; 1987; 27 Suppl 1():9-20. PubMed ID: 3123242
[TBL] [Abstract][Full Text] [Related]
14. Growth hormone and prolactin stimulation by Madopar in Parkinson's disease.
Martinez-Campos A; Giovannini P; Parati E; Novelli A; Caraceni T; Müller EE
J Neurol Neurosurg Psychiatry; 1981 Dec; 44(12):1116-23. PubMed ID: 7334406
[TBL] [Abstract][Full Text] [Related]
15. Preliminary experience with Madopar HBS: clinical observations and plasma levodopa concentrations.
Fischer PA; Baas H
Eur Neurol; 1987; 27 Suppl 1():81-7. PubMed ID: 3322840
[TBL] [Abstract][Full Text] [Related]
16. Controlled-release levodopa/benserazide (Madopar HBS): clinical observations and levodopa and dopamine plasma concentrations in fluctuating parkinsonian patients.
Ceballos-Baumann AO; von Kummer R; Eckert W; Weicker H
J Neurol; 1990 Feb; 237(1):24-8. PubMed ID: 2181074
[TBL] [Abstract][Full Text] [Related]
17. Open study of Madopar HBS, a new formulation of levodopa with benserazide, in 13 patients with Parkinson's disease and 'on-off' fluctuations.
Quinn NP; Marion MH; Marsden CD
Eur Neurol; 1987; 27 Suppl 1():105-13. PubMed ID: 3322834
[TBL] [Abstract][Full Text] [Related]
18. Long-term treatment with Madopar HBS in parkinsonians with fluctuations.
Chouza C; Aljanati R; Caamaño JL; De Medina O; Scaramelli A; Buzó R; Plachín V; Fernandez A; Romero S
Adv Neurol; 1990; 53():519-26. PubMed ID: 2122654
[TBL] [Abstract][Full Text] [Related]
19. Madopar HBS: slow-release levodopa and benserazide in parkinsonian patients presenting marked fluctuations in symptoms on standard L-dopa treatment.
Jensen NO; Dupont E; Hansen E; Mikkelsen B; Mikkelsen BO
Eur Neurol; 1987; 27 Suppl 1():68-72. PubMed ID: 3428310
[TBL] [Abstract][Full Text] [Related]
20. Madopar HBS in nocturnal symptoms of Parkinson's disease.
Jansen EN; Meerwaldtt JD
Adv Neurol; 1990; 53():527-31. PubMed ID: 2239493
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
